Compare VREX & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | KALV |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 483.7M | 551.2M |
| IPO Year | N/A | N/A |
| Metric | VREX | KALV |
|---|---|---|
| Price | $11.89 | $15.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $16.67 | ★ $27.17 |
| AVG Volume (30 Days) | 283.5K | ★ 1.4M |
| Earning Date | 02-05-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $844,600,000.00 | $1,426,000.00 |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $4.15 | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.14 | N/A |
| 52 Week Low | $6.76 | $7.30 |
| 52 Week High | $15.46 | $17.30 |
| Indicator | VREX | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 50.69 |
| Support Level | $11.71 | $14.70 |
| Resistance Level | $12.54 | $16.30 |
| Average True Range (ATR) | 0.32 | 0.86 |
| MACD | 0.04 | -0.22 |
| Stochastic Oscillator | 41.82 | 14.62 |
Varex Imaging Corp designs and manufactures X-ray imaging components. It operates in two segments Medical and Industrial. The Medical segment, which is the key revenue driver, designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, generators, and heat exchangers among other products. The Industrial segment designs, manufactures, sells, and services Linatron X-ray accelerators, X-ray tubes, digital flat panel detectors, high-voltage connectors, and coolers. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA) and the rest from the Americas and Asia Pacific region.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.